Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology. The Company's therapeutic proteins for immunology include CGEN-15001T, CGEN-15022, CGEN-15029, CGEN-15049 and CGEN-15092, which are based on B7/CD28-like immune checkpoint candidates. It offers various infrastructure platforms, which include LEADS, MED and LINKS, which integrates its scientific understandings and predictive models. It offers various target discovery platforms, which include Antibody-Drug Conjugate Cancer Therapy Discovery Platform, Other Discovery Approaches for Immunomodulatory Proteins and Biomarker Discovery Approaches.